The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2021 | Challenges of KRAS-targeting for lung cancer therapy
Colin Lindsay, BSc, MBChB, MRCP, PhD, Christie NHS Foundation Trust, Manchester, UK, discusses challenges in G12C targeting for the treatment of patients with KRAS-mutant lung cancer, commenting on the role of x-ray crystallography in drug development and the need for novel approaches for targeting other KRAS mutations, such as G12V and G12D. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.
Disclosures
Colin Lindsay, BSc, MBChB, MRCP, PhD, has participated in an advisory role for Amgen and cbpartners; has participated in clinical trials with Amgen, Apollomics, BI, Mirati Therapeutics, Revolution Medicines and Roche; and has participated in a review paper coordinated by Amgen.
